美国成年女性沙眼衣原体血清流行率:NHANES 2013-2016
该横断面研究纳入2013至2016年美国国家健康与营养调查中1725名18至39岁提供血清和尿液的女性,用ELISA与MBA两种方法检测抗沙眼衣原体Pgp3 IgG并计算加权血清流行率。ELISA测得总体血清流行率为30.0%(95%CI 25.5-35.0),MBA为29.4%(95%CI 25.8-33.0);非西班牙裔黑人女性血清流行率显著更高。
要点
- 美国18-39岁女性沙眼衣原体Pgp3 IgG血清流行率约30%,提示暴露普遍。
- 非西班牙裔黑人女性血清流行率68.0%,显著高于非西班牙裔白人(21.4%)。
- MBA检测与尿液现症检出、过去一年诊断及盆腔炎治疗史呈较高阳性一致。
核心结论
- ELISA与MBA两种血清学方法均显示美国年轻成年女性家庭人群中沙眼衣原体Pgp3抗体呈高流行。
- 沙眼衣原体暴露存在明显种族/民族差异,非西班牙裔黑人女性易感性更高。
研究设计与样本
- 横断面研究,纳入2013至2016年NHANES中1725名18至39岁提供血清和尿液的女性。
- 以ELISA与MBA检测抗沙眼衣原体Pgp3 IgG,计算加权血清流行率,并用多变量Poisson回归分析相关因素。
主要发现
- ELISA测得总体血清流行率为30.0%(95%CI 25.5-35.0),MBA为29.4%(95%CI 25.8-33.0)。
- 两法总体一致率为87.1%(1503/1725)。
- MBA检测与尿液现症沙眼衣原体检出阳性一致率86%(36/42),与过去一年诊断一致率81.8%(27/33),与盆腔炎治疗史一致率60.7%(37/61)。
- MBA测得非西班牙裔黑人女性血清流行率68.0%(aPR=2.7,95%CI 2.3-3.3),墨西哥裔美国人30.9%(aPR=1.5,95%CI 1.2-1.9),其他西班牙裔35.0%(aPR=1.9,95%CI 1.4-2.5),均高于非西班牙裔白人21.4%。
- 终生性伴侣数更多及初次性行为年龄更小也与更高血清流行率相关。
关键数值与推荐
- ELISA血清流行率30.0%(95%CI 25.5-35.0),MBA血清流行率29.4%(95%CI 25.8-33.0)。
- 非西班牙裔黑人女性aPR=2.7(95%CI 2.3-3.3),墨西哥裔美国人aPR=1.5(95%CI 1.2-1.9),其他西班牙裔aPR=1.9(95%CI 1.4-2.5)。
临床怎么用
- 血清学Pgp3 IgG可用于评估人群沙眼衣原体暴露水平,但不直接等同于现症感染。
- 应关注非西班牙裔黑人女性等高血清流行群体的筛查与防控。
- 性伴侣数多与初次性行为年龄小提示暴露风险升高,可辅助风险评估。
局限性
- 原文摘要未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chlamydia trachomatis is the most common nationally notifiable sexually transmitted infection in the United States; however, the seroprevalence of C. trachomatis infection is unknown. METHODS: This cross-sectional study was conducted among 1725 females aged 18 to 39 years who provided serum and urine samples in the 2013 through 2016 National Health and Nutrition Examination Surveys. Presence of anti-C. trachomatis Pgp3 immunoglobulin G (IgG) was determined using both an enzyme-linked immunosorbent assay (ELISA) and multiplex bead array (MBA). Weighted seroprevalence estimates were calculated. Correlates of seroprevalence were examined by multivariable Poisson regression. RESULTS: In 2013 through 2016, overall seroprevalence of C. trachomatis Pgp3 IgG was 30.0% (95% confidence interval [CI], 25.5-35.0) as measured by ELISA and 29.4% (95% CI, 25.8-33.0) as measured by the MBA assay. Overall agreement between tests was 87.1% (1503/1725). There was a high positive agreement by the MBA assay with current detection of chlamydia in urine (86% [36/42]), a past-year diagnosis of chlamydia (81.8% [27/33]), and a history of treatment for pelvic inflammatory disease (60.7% [37/61]). Seroprevalence of C. trachomatis Pgp3 IgG, as measured by MBA, was significantly higher among non-Hispanic Blacks (68.0%; adjusted prevalence ratio (aPR) = 2.7 [95% CI, 2.3-3.3]), Mexican Americans (30.9%; aPR = 1.5 [95% CI, 1.2-1.9]), and other Hispanics (35.0%; aPR = 1.9 [95% CI, 1.4-2.5]) compared with non-Hispanic Whites (21.4%). A higher lifetime number of sexual partners and a younger age at sexual debut was also associated with higher seroprevalence. CONCLUSION: Both the ELISA and MBA serologic assays revealed a high prevalence of antibodies to C. trachomatis Pgp3 in young adult females in the US household population. There were major racial/ethnic disparities in exposure to C. trachomatis, with increased vulnerability among non-Hispanic Black females.
引用
- Petersen MR, Patel EU, Grabowski MK, et al. Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys. Clin Infect Dis. 2021. PMID: 33367598. doi:10.1093/cid/ciaa1879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。